Why 70% of Pharma Expansions Into MENA Fail And How to Avoid It
- Mar 18
- 2 min read
In 2022, a European biotech SME with a promising oncology product decided to enter Saudi Arabia. Solid dossier. Budget allocated. Leadership enthusiastic. Eighteen months later, they still had no SFDA registration, not because the product was insufficient, but because they had confused the SFDA procedure with that of the UAE MOH: two authorities with radically different requirements. 18 months of delay. €400,000 of wasted budget. An American competitor had in the meantime secured exclusivity on their segment. (Anonymized case, composite of several ground-level mandates.)
This case is not an exception. It's the rule.
The vast majority of North American and European pharma companies that attempt a MENA expansion fail, or abandon before signing a single agreement.
Not for lack of ambition. Not for lack of budget. For lack of a ground-level guide.
Mistake #1: Ignoring Multi-Jurisdictional Regulatory Complexity
MENA is not one market. It's a mosaic of markets, each with its own health authorities, registration requirements, and timelines. Confusing procedures between two jurisdictions can cost 6 to 18 months. For a pharma SME, that's often the difference between a successful launch and an abandoned project.
What you need to know: navigating these authorities requires direct experience submitting dossiers, not just reading public guidelines.
Mistake #2: Entering Without Local Intelligence
Entering a MENA market without ground-level knowledge means investing blind. Gulf, Maghreb, and Levant markets each have their own commercial codes, competitive dynamics, and key players.
What you need to know: stakeholder mapping and real competitive analysis are the first steps of any serious market entry strategy.
Mistake #3: Choosing the Wrong Local Partner
This is the most costly mistake, and the most common. Without a verified network, choosing a distributor or co-developer internationally is essentially drawing from a hat.
What you need to know: the partner selection process is the cornerstone of any successful expansion. Its rigor determines the quality of the final agreement.
Mistake #4: Underestimating Cultural and Commercial Barriers
A solid agreement on paper can collapse at the negotiating table. Companies without cultural guidance in the room lose deals they believed were won, not on substance, but on form.
What you need to know: cultural intelligence is acquired through direct field experience, deal by deal. It cannot be delegated to a translator.
Why Act in 2025 and Not 2026
Pharma and biotech SMEs that don't initiate their MENA strategy before end of 2025 will pay significantly more for market entry in 2026–2027. First-tier distributors are being locked up by players already in motion. Exclusivity windows are closing. Regulatory timelines lengthen as health authorities receive more dossiers. This isn't a projection: it's the dynamic observed in every market opening over the past 10 years.
Do you recognize your situation in this article?
Book 45 minutes with us.
No commitment.
Response within 48h.
Comments